Engen Bio, Inc.

Hyseq, Inc.

Mark Alfenito

Mark Baer

Doris Bucher

Geoffrey T Yarranton

The present invention is directed generally to M1 polypeptides that can be utilized as vaccines and/or antigens for generation of anti-M1 polypeptide antibodies for prophylactic treatment of individuals who are susceptible to infection by influenza virus. The anti-M1 polypeptide antibodies of the invention are useful for treatment of individuals infected with influenza virus, or useful for prophylactic treatment of individuals who are susceptible to infection by influenza virus, or for immune-suppressed individuals who cannot generate an effective antibody response.

Influenza vaccine and therapy

The invention relates to methods for preparing nucleic acid pools useful in hybridization studies. Such methods allow hybridization conditions, such as time, temperature, ionic strength, etc., to be adjusted to increase the likelihood that hybridization to the nucleic acids within each pool is within the linear range of detection (i.e., detectable but not saturating). The methods rely on pooling nucleic acids derived from a sample, based on the degree of representation within the sample, i.e., nucleic acids having similar degrees of representation within in a sample are combined into a pool. The invention also provides arrays and kits produced from pooled nucleic acids, and an improved method for identifying a nucleic acid and/or its representation in a sample.

Growing community of inventors

Redwood City, CA, United States of America

Mark Alfenito